Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kivu Bioscience Inc.
ViroMissile, Inc.
MacroGenics
Avacta Life Sciences Ltd
Solve Therapeutics
M.D. Anderson Cancer Center
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
University Health Network, Toronto
Medigene AG
Shanghai PerHum Therapeutics Co., Ltd.
Brown University
Xencor, Inc.
Prelude Therapeutics
Pfizer
Celon Pharma SA
Adaptimmune
Corvus Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Emory University
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
MacroGenics
Hebei Senlang Biotechnology Inc., Ltd.
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tocagen Inc.
Merrimack Pharmaceuticals
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Altor BioScience
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Valerio Therapeutics
Valerio Therapeutics